Leuprolide Evidence Guide
Leuprolide (Lupron) is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty - one of the broadest indication profiles of any peptide drug in this library. With 40+ years of clinical use and extensive Phase 3 data across multiple indications, it is the reference GnRH agonist. A highly validated compound by any standard.
Our Take
Leuprolide (Lupron) is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty - one of the broadest indication profiles of any peptide drug in this library. With 40+ years of clinical use and extensive Phase 3 data across multiple indications, it is the reference GnRH agonist. A highly validated compound by any standard.
- Evidence context
- Prostate cancer hormone therapy, endometriosis, uterine fibroids, precocious puberty, GnRH agonist reference compound
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 7.5mg IM monthly (prostate cancer); 3.75mg IM monthly (endometriosis)
Benefits and Evidence
- Advanced Prostate Cancer: Level A, includes human evidence - Standard androgen deprivation therapy for advanced and metastatic prostate cancer. Achieves castrate testosterone in >93% of patients. Decades of clinical experience and RCT data support efficacy.
- Endometriosis Management: Level A, includes human evidence - Significantly reduces endometriosis-related pain and lesion size through estrogen suppression. Typically used for 6 months with hormonal add-back to mitigate bone loss and menopausal symptoms.
- Central Precocious Puberty: Level A, includes human evidence - First-line treatment for central precocious puberty. Suppresses premature pubertal development, reduces growth velocity to prepubertal rates, and preserves predicted adult height.
- Uterine Fibroid Shrinkage: Level A, includes human evidence - Pre-surgical treatment reduces fibroid volume by 35-65% over 3-6 months, facilitating less invasive surgery. Effect reverses after discontinuation.
Side Effects and Warnings
- Hot flashes (most common)
- Decreased libido
- Erectile dysfunction (males)
- Bone mineral density loss
- Injection site reactions
- Mood changes, irritability, depression
- Weight gain
- Fatigue and weakness
Research Dosage References
- <strong>Intramuscular or subcutaneous depot</strong> - 7.5 mg (monthly), 22.5 mg (3-month), 30 mg (4-month), 45 mg (6-month) - Per depot interval - Lupron Depot formulation. Injection by healthcare provider. Anti-androgen cover for first 2-4 weeks in prostate cancer to prevent flare.
- <strong>Subcutaneous (daily)</strong> - 1 mg/day - Daily - Used in IVF protocols and some pediatric applications. Less common than depot formulations.
- <strong>Subcutaneous implant</strong> - 65 mg - Every 12 months - Viadur implant for prostate cancer. Provides continuous release for one year. No longer widely available.
Mechanism of Action
Leuprolide achieves hormonal suppression via GnRH receptor desensitization: 1. Supraphysiological GnRH receptor activation: Binds pituitary GnRH receptors with high affinity, initially triggering a surge of LH, FSH, and downstream sex hormones (flare phase, 7-14 days). 2. Receptor desensitization and downregulation: Continuous occupancy leads to receptor internalization, uncoupling from G-proteins, and reduced receptor expression. 3. Gonadotropin suppression: LH and FSH fall to hypogonadal levels, eliminating the stimulus for gonadal steroid production. 4. End-organ effect: Testosterone falls below 50 ng/dL (surgical castrate level) in men; estradiol falls to menopausal levels in women. Achieves the therapeutic effect in hormone-dependent conditions.
Legal Status
FDA-approved prescription medication. Multiple formulations and brand names (Lupron, Eligard, Fensolvi). Not a controlled substance.
Primary Sources
- Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New England Journal of Medicine, 1984.
- Depot leuprolide acetate for the treatment of endometriosis. Journal of Clinical Endocrinology & Metabolism, 1988.
- Long-term follow-up of central precocious puberty treated with GnRH analogs. Journal of Pediatric Endocrinology & Metabolism, 2008.
Quick Answers
Where is the strongest evidence for Leuprolide?
Leuprolide (Lupron) is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty - one of the broadest indication profiles of any peptide drug in this library. With 40+ years of clinical use and extensive Phase 3 data across multiple indications, it is the reference GnRH agonist. A highly validated compound by any standard. Evidence context: Prostate cancer hormone therapy, endometriosis, uterine fibroids, precocious puberty, GnRH agonist reference compound.
What are the main side effects of Leuprolide?
Leuprolide side effects and warning signals include Hot flashes (most common), Decreased libido, Erectile dysfunction (males), Bone mineral density loss, and Injection site reactions.
What evidence level is Leuprolide?
Leuprolide is rated Level A; the listed research status is FDA Approved.